TGFB1 and idiopathic pulmonary fibrosis: A retrospective study in idiopathic pulmonary fibrosis (IPF), which is discussed to be driven by aberrant TGFβ (12), found that patients treated with Pirfenidone had a significantly reduced risk of developing lung cancer during their follow-up phase (13).